Africa Injectable Drugs Market Report

Africa Injectable Drugs Market Size

The Africa Injectable Drugs Market is estimated to grow from USD 664.76 billion in 2024 to USD 1169.80 billion in 2033, representing a CAGR 7.32%.

Injectable drugs are sterile pharmaceutical formulations administered via parenteral routes, primarily intravenous, intramuscular, and subcutaneous, used in hospitals, clinics, and community health settings across the continent. These drugs are critical in managing acute and chronic conditions, including infectious diseases, cancer, diabetes, and maternal health complications. The sector is shaped by urgent public health needs, with injectables constituting notable share of essential medicines on national lists in sub-Saharan African countries. Also, millions of injections are administered annually across Africa, primarily in public health programs targeting HIV, tuberculosis, and immunization. However, infrastructure limitations persist: low percentage of healthcare facilities in rural areas have reliable cold chain storage, complicating the delivery of temperature-sensitive biologics and vaccines, and underscoring the operational complexity of scaling injectable therapies across diverse regional contexts.

MARKET DRIVERS

Rising Burden of Chronic and Infectious Diseases

The escalating prevalence of both communicable and non-communicable diseases is a primary driver of demand for injectable drugs across Africa. As per the World Health Organization, the continent accounts for nearly 70% of global HIV infections, with 28.3 million people receiving antiretroviral therapy in 2023, a significant portion of which includes long-acting injectable regimens such as cabotegravir and rilpivirine. Simultaneously, the incidence of diabetes is surging, with the International Diabetes Federation estimating that 24.2 million adults in Africa had diabetes in 2023, a figure projected to rise to 55 million by 2045. Insulin, a life-saving injectable, remains underutilized due to access gaps, yet demand is intensifying. In Nigeria, insulin prescriptions increased, reflecting growing diagnosis rates. These dual epidemics necessitate robust supply chains for injectables, particularly in decentralized care models where self-administration and long-acting formulations are increasingly prioritized.

Expansion of Vaccination and Immunization Programs

Large-scale immunization initiatives are significantly amplifying the use of injectable drugs across Africa. The WHO African Region introduced 12 new vaccines between 2015 and 2023, including those for HPV, pneumococcal disease, and malaria, all administered via injection. As of 2023, Gavi, the Vaccine Alliance, supported immunization programs in several African countries, facilitating millions of vaccine doses delivered annually. The rollout of the RTS,S malaria vaccine in Ghana, Kenya, and Malawi has already protected millions. Additionally, the African Union’s Agenda 2063 emphasizes regional vaccine self-sufficiency, prompting investments in local production. In 2023, Senegal’s Institut Pasteur de Dakar launched a vaccine manufacturing facility, reducing import dependency. These developments are institutionalizing injectable delivery systems and reinforcing the need for trained personnel, cold chain infrastructure, and safe injection practices across primary healthcare networks.

MARKET RESTRAINTS

Inadequate Healthcare Infrastructure and Distribution Networks

The continent’s fragmented and under-resourced healthcare infrastructure is a critical restraint on the Africa injectable drugs market. Like, only a limited portion of health facilities in sub-Saharan Africa have access to electricity, severely limiting refrigeration for temperature-sensitive injectables such as insulin and monoclonal antibodies. In rural Ethiopia, health posts lack functional cold chain equipment. Road connectivity remains poor. Furthermore, hospital bed density averages just 2.3 per 1,000 people, well below the global average of 5.8. These systemic deficiencies impede the storage, transportation, and administration of sterile injectable products, particularly in remote areas, resulting in stockouts, wastage, and compromised treatment continuity, thereby constraining market growth despite high medical need.

Shortage of Trained Healthcare Personnel

The scarcity of skilled medical professionals capable of safely administering injectable therapies severely limits market expansion. As per the WHO, Africa bears 24% of the global disease burden but has only 3% of the world’s health workforce, with a physician density of just 0.25 per 1,000 people, far below the recommended 1 per 1,000. In Malawi, there is extremely low density of physians doctor, making routine injection administration a logistical challenge. Nurses and community health workers often lack formal training in aseptic techniques, contributing to high rates of unsafe injections. This deficit discourages investment in complex injectable therapies, such as biologics and long-acting antipsychotics, which require specialized handling and monitoring, ultimately limiting patient access and undermining the scalability of injectable drug programs.

MARKET OPPORTUNITIES

Growth of Local Pharmaceutical Manufacturing

The push for pharmaceutical self-reliance presents a transformative opportunity for the Africa injectable drugs market. The African Union’s Pharmaceutical Manufacturing Plan for Africa (PMPA) aims to produce 60% of the continent’s medicines locally by 2040, reducing reliance on imports that currently exceed 90%, as stated by the African Development Bank. Similarly, South Africa’s Aspen Pharmacare operates one of the continent’s most advanced injectable manufacturing facilities, producing oncology and critical care drugs for 18 African nations. These developments, supported by African Medicines Agency (AMA) regulatory harmonization efforts, are laying the foundation for sustainable, scalable injectable drug production tailored to regional disease profiles and distribution realities.

Adoption of Long-Acting Injectable Therapies

The emergence of long-acting injectable (LAI) formulations is creating new avenues for improving treatment adherence and reducing healthcare burden across Africa. LAIs for HIV, such as cabotegravir and rilpivirine, require administration only every one to two months, a significant advantage in settings with limited clinic access. For mental health, LAIs for schizophrenia and bipolar disorder are gaining traction. Additionally, the development of temperature-stable LAIs, such as those using nano-suspension technology, addresses cold chain limitations. These innovations align with Africa’s decentralized care models, enabling community health workers to administer treatments with fewer visits, thereby expanding access and improving long-term health outcomes.

MARKET CHALLENGES

Regulatory Fragmentation Across National Markets

The lack of harmonized regulatory frameworks, which impedes drug approval, quality assurance, and cross-border distribution is a major challenge facing the Africa injectable drugs market. Each of the 54 African nations maintains distinct regulatory requirements, leading to prolonged registration timelines. In 2023, only few countries had functional national medicines regulatory authorities meeting WHO benchmark levels. This fragmentation delays the introduction of novel injectables, including biosimilars and advanced vaccines, and fosters reliance on substandard or falsified products. The absence of a unified quality control mechanism also undermines confidence in locally manufactured injectables, discouraging investment and limiting regional scalability despite growing production capacity.

Risk of Medication Errors and Unsafe Injection Practices

The administration of injectable drugs across Africa is frequently compromised by medication errors and unsafe practices, posing serious patient safety risks. Additionally, syringe reuse remains prevalent. These risks are exacerbated by overcrowded facilities, inadequate training, and limited access to auto-disable syringes. Without systemic improvements in clinical governance and injection safety protocols, the expansion of injectable drug use may inadvertently increase iatrogenic harm, undermining public trust and therapeutic efficacy.

SEGMENTAL ANALYSIS

By Molecule Type Insights

The small molecule segment dominated the Africa injectable drugs market by capturing an estimated 66.2% share in 2024. This pre-eminence is primarily driven by the widespread use of chemically synthesized injectables in treating acute and infectious diseases, which remain the leading causes of morbidity and mortality across the continent. The reliance on injectable antibiotics and antimalarials in primary healthcare settings, where over 80% of severe malaria cases are managed with intravenous artesunate, according to the World Health Organization, is a key factor. Besides, small molecule injectables such as diazepam for seizures and lidocaine for pain management are integral to emergency care in under-resourced clinics. Their stability at ambient temperatures further enhances their suitability for decentralized distribution. Coupled with lower manufacturing complexity and cost, these attributes solidify the dominance of small molecule injectables in Africa’s therapeutic landscape.

The large molecule segment is projected to grow at the fastest CAGR of 13.6% from 2025 to 2033. This acceleration is fueled by increasing adoption of biologic therapies, particularly monoclonal antibodies and recombinant proteins, in managing chronic conditions such as cancer, diabetes, and autoimmune disorders. The expansion of oncology care infrastructure is a major driver. Additionally, global health initiatives are facilitating access to high-cost biologics—Gavi supported the introduction of the monoclonal antibody nirsevimab for infant respiratory syncytial virus (RSV), marking a milestone in pediatric biologic delivery. Furthermore, temperature-stable formulations and lyophilized products are overcoming cold chain limitations, enabling broader deployment of large molecule therapies in resource-constrained environments.

By Drug Class Insights

The insulin segment held the largest share of the Africa injectable drugs market at 27.5% of total revenue in 2024. This growth is underpinned by the escalating prevalence of diabetes and the absolute dependence on injectable insulin for type 1 and advanced type 2 diabetes management. With 24.2 million adults in Africa living with diabetes—a number expected to double by 2045—insulin demand is intensifying, particularly in urban centers. In Nigeria, insulin prescriptions is rising, driven by improved diagnosis rates and public awareness campaigns. However, access remains limited: only limited number of 4 insulin-dependent patients receives adequate supply. The dominance of insulin is further reinforced by its inclusion in national essential medicines lists across 40 African countries and its use in both public health programs and private clinics, making it the most widely administered injectable biologic on the continent.

The Monoclonal antibodies (mAbs) segment is anticipated to register the highest CAGR of 15.2% between 2025 and 2033 and is emerging as the fastest-growing drug class in the Africa injectable drugs market. This rapid expansion is driven by the increasing integration of mAbs into cancer and infectious disease treatment protocols. Additionally, the rollout of long-acting mAbs for HIV prevention, such as lenacapavir and broadly neutralizing antibodies in clinical trials, is reshaping prophylactic strategies. Moreover, donor funding from organizations like PEPFAR and Unitaid is subsidizing procurement, reducing cost barriers. These developments signal a paradigm shift from traditional small-molecule therapies toward targeted, high-efficacy biologics tailored to Africa’s evolving disease burden.

By Application Insights

The Infectious diseases segment was the prevailing application in the Africa injectable drugs market by commanding an estimated 49.4% share of total usage in 2024. This dominance is due to the continent’s high burden of communicable illnesses, including HIV, tuberculosis, malaria, and vaccine-preventable diseases, which collectively require injectable interventions for effective management. According to the World Health Organization, millions of vaccine doses were administered via injection in Africa in 2023, supported by Gavi and UNICEF supply chains. Besides, parenteral antiretrovirals remain standard in maternity wards across sub-Saharan Africa. Severe bacterial infections necessitate injectable antibiotics like ceftriaxone. The reliance on injectables in emergency and inpatient care, where oral formulations are ineffective, further entrenches their centrality in combating infectious outbreaks and sustaining public health programs across diverse healthcare settings.

The oncology segment is emerging as the fastest-growing application and is projected to expand at a CAGR of 14.1% from 2025 to 2033. This surge is driven by rising cancer incidence and improved diagnostic capabilities across urban medical centers. The International Agency for Research on Cancer reports that new cancer cases in Africa will increase by 81% by 2040, with breast, cervical, and prostate cancers leading the burden. In response, countries like Egypt and South Africa have expanded access to injectable chemotherapy and biologic agents—doxorubicin, paclitaxel, and trastuzumab—through national cancer control plans. Additionally, donor-funded programs such as Pink Ribbon Red Ribbon are supporting cervical cancer treatment with injectable cisplatin. The integration of oncology into universal health coverage schemes further accelerates demand, positioning injectable cancer therapies as a critical frontier in Africa’s evolving healthcare priorities.

REGIONAL ANALYSIS

South Africa was the most prominent position in the Africa injectable drugs market by capturing an estimated 31.3% of regional revenue in 2024. The country’s market growth is anchored in its advanced healthcare infrastructure, robust pharmaceutical manufacturing base, and high prevalence of chronic diseases requiring injectable therapies. It is home to Aspen Pharmacare, one of the continent’s largest producers of sterile injectables, including oncology and critical care drugs distributed across 18 African nations. The public sector administers millions of injections annually, primarily for HIV, tuberculosis, and diabetes. Besides, South Africa hosts the only fully operational cancer treatment centers offering monoclonal antibodies and biosimilars in sub-Saharan Africa. Its regulatory maturity and integration into global health initiatives further position it as a hub for clinical trials and technology transfer in advanced injectable therapeutics.

Egypt commands a significant share of the Africa injectable drugs market, establishing itself as a key pharmaceutical hub in North Africa. The country’s strategic position is reinforced by its long-standing local manufacturing capacity, with several pharmaceutical plants producing sterile formulations. The government’s Vision 2030 includes expanding access to insulin and antineoplastics, with high diabetes prevalence aong adults. Besides, Egypt has become a regional leader in biosimilar production. Its participation in the African Medicines Agency (AMA) and alignment with WHO prequalification standards enhance its role as a supplier of affordable, high-quality injectables across the continent.

Kenya holds a notable share of the market and is positioning itself as a growing pharmaceutical and distribution hub in East Africa. The country’s market status is defined by its expanding healthcare access programs and regional logistics connectivity. The country is a pilot site for long-acting injectable HIV treatments. Additionally, Kenya is advancing local production through the Kenya Medical Supplies Authority (KEMSA) and private firms. Its role as a regional distribution node, serving Uganda, Rwanda, and South Sudan, further amplifies demand for temperature-controlled injectable logistics, supported by investments in cold chain infrastructure from Gavi and the World Bank.

Nigeria is reflecting its status as the continent’s most populous nation with a rapidly expanding healthcare demand, as reported by the National Agency for Food and Drug Administration and Control (NAFDAC). The country’s market is driven by high disease burden, including the largest HIV population in the world and rising diabetes prevalence. Injectable insulin and antibiotics constitute a major share of hospital-administered drugs in major cities like Lagos and Abuja. However, distribution remains fragmented. Despite challenges, Nigeria’s pharmaceutical market is projected to grow, driven by public-private partnerships and donor-funded immunization campaigns.

Ethiopia is establishing itself as a strategic player in the Horn of Africa. The country’s market status is shaped by its large population, government-led health expansion, and focus on maternal and child health programs. Ethiopia administers a large number of vaccine injections annually through its nationwide immunization drive, achieving DTP3 coverage. The Federal Ministry of Health has also scaled up injectable oxytocin and magnesium sulfate to reduce maternal mortality, which remains high at 412 deaths per 100,000 live births. While local manufacturing is limited, Ethiopia is developing its pharmaceutical sector through the Ethiopian Pharmaceutical Manufacturing Industry Cluster. Its role as a logistics gateway for regional aid organizations further enhances the flow of donor-supplied injectables, positioning Ethiopia as a critical node in public health delivery across East Africa.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Pfizer Inc, Johnson & Johnson (Janssen), Novartis AG, Roche Holding AG, Sanofi, GlaxoSmithKline (GSK), AstraZeneca plc, Merck & Co., Eli Lilly and Company, AbbVie Inc., Amgen Inc., Baxter International, B. Braun, Fresenius Kabi, Hikma Pharmaceuticals, Cipla Ltd., Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Lupin Limited, Aurobindo Pharma, Aspen Pharmacare, Adcock Ingram, SAIDAL Group, Julphar, and Cipla Quality Chemical Industries (CiplaQCIL).

The competition in the Africa injectable drugs market is shaped by a dynamic interplay between multinational pharmaceutical giants, regional manufacturers, and public health stakeholders. While global firms such as Pfizer and Sanofi dominate through vaccine supply and donor-backed programs, African-based companies like Aspen Pharmacare are gaining ground by offering cost-effective, locally produced sterile formulations. The market is increasingly influenced by regulatory harmonization under the African Medicines Agency, which levels the playing field for quality-approved products. Competition is less price-driven and more focused on reliability, temperature resilience, and integration into national health systems. Emerging players are leveraging biosimilars and long-acting injectables to address chronic disease gaps, while digital logistics and cold chain innovation are becoming key differentiators in ensuring last-mile delivery across diverse and often under-resourced healthcare environments.

Top Players in the Africa Injectable Drugs Market

Pfizer has established a significant presence in the Africa injectable drugs market through its supply of essential vaccines and critical care injectables, including pneumococcal conjugate vaccine (Prevnar 13) and emergency antibiotics. The company has strengthened its regional footprint by partnering with Gavi and UNICEF to ensure large-scale, equitable distribution across low-income countries. In 2023, Pfizer launched a temperature-stable formulation of its injectable antibiotic azithromycin, specifically designed for use in areas with unreliable cold chains, enhancing accessibility in rural clinics. It also expanded its collaboration with the African Union to support local fill-finish capacity, enabling technology transfer to African manufacturers. By aligning with public health priorities and investing in heat-resistant formulations, Pfizer has reinforced its role as a key enabler of safe and scalable injectable therapy delivery across diverse African healthcare environments.

Sanofi has become a pivotal player in the Africa injectable drugs market through its leadership in vaccine delivery and diabetes care. The company supplies over 200 million doses of injectable vaccines annually to African countries, including its widely used yellow fever and meningitis A vaccines, in partnership with Gavi and the WHO. In 2022, Sanofi initiated a regional insulin access program in Kenya and Nigeria, providing affordable prefilled insulin pens and training healthcare workers on injection safety. Additionally, the company invested in cold chain logistics through its “Last Mile” initiative, which deploys solar-powered refrigerators to remote clinics in Niger and Malawi, as reported by the Sanofi Access to Medicines program. These efforts reflect a strategic focus on overcoming infrastructure barriers while expanding access to life-saving injectables, particularly for non-communicable diseases, positioning Sanofi as a long-term contributor to Africa’s evolving therapeutic landscape.

Aspen Pharmacare has emerged as a leading African-based pharmaceutical company with a dominant role in sterile injectable manufacturing across the continent. Headquartered in South Africa, Aspen produces a wide range of generic injectables, including oncology drugs, cardiovascular agents, and antibiotics, distributed across 18 African nations. In 2023, the company launched a biosimilar version of trastuzumab for breast cancer treatment, significantly reducing costs for public health systems. It also expanded its aseptic manufacturing capacity at its Gqeberha facility to meet growing demand for hospital-grade injectables. By leveraging local production, complying with WHO prequalification standards, and supplying through public tenders, Aspen has reduced dependency on imports and enhanced supply resilience. Its strategic focus on high-burden therapeutic areas and regulatory alignment with international bodies solidifies its position as a cornerstone of Africa’s self-reliant injectable drug ecosystem.

Top Strategies Used by Key Market Participants

Key players in the Africa injectable drugs market are adopting multifaceted strategies to expand access and strengthen their operational footprint. Companies are forming strategic alliances with governments and global health organizations to integrate into national procurement systems. Investment in heat-stable formulations and single-dose packaging addresses cold chain and safety challenges in remote areas. Expanding local manufacturing and fill-finish capabilities through technology transfer agreements reduces import reliance and accelerates supply timelines. Firms are also enhancing distribution networks using solar-powered cold storage and drone delivery pilots in hard-to-reach regions. Additionally, training programs for healthcare workers on injection safety and biosimilar use are being implemented to improve clinical outcomes and build trust in high-quality generic injectables across public and private healthcare settings.

RECENT MARKET DEVELOPMENTS

• In June 2023, Pfizer launched a heat-stable formulation of azithromycin for trachoma control in sub-Saharan Africa, enabling distribution in regions without reliable refrigeration and expanding treatment access.
• In September 2022, Sanofi deployed solar-powered cold chain units across 500 clinics in Niger and Malawi, enhancing the safe storage and delivery of temperature-sensitive injectable vaccines.
• In January 2024, Aspen Pharmacare initiated commercial production of a WHO-prequalified trastuzumab biosimilar at its South African facility, reducing costs for breast cancer treatment in public hospitals.
• In March 2023, Sanofi expanded its insulin access program to include prefilled pens in Nigeria and Kenya, improving patient adherence and reducing injection errors in diabetes care.
• In November 2023, Pfizer entered a technology transfer agreement with the African Union to support local fill-finish manufacturing of injectable antibiotics, strengthening regional production capacity

MARKET SEGMENTATION

This research report on the Africa Zero Liquid Discharge System Market is segmented and sub-segmented into the following categories.

By Molecule Type

• Small Molecule
• Large Molecule

By Drug Class

• Blood Factors
• Cytokines
• Peptide Hormone
• Immunoglobulin
• Monoclonal Antibodies (mAbs)
• Insulin
• Others

By Application

• Oncology
• Neurology
• Cardiovascular Diseases
• Autoimmune Diseases
• Infectious Diseases
• Pain
• Others

By Country

• South Africa
• Nigeria
• Rest of Africa